MONASH IVF GROUP

Basis.

• All figures are A$ million unless stated.

• The five most recent fiscal years (FY22–FY26) come from the FY26 Remuneration Report's five-year table, the FY24 4E and the FY22 4E.

• Balance sheet and cash-flow data are presented for FY23–FY26, where verified primary data were extracted.

Gross profit. Monash IVF reports expenses by nature (employee benefits, consumables, occupancy and so on). It does not report cost of sales or gross profit, so gross profit and gross margin are not publicly disclosed.

Income statement (FY22–FY26)

Sources: FY26 Remuneration Report s.6.0 (five-year table); FY24 4E; FY22 4E. Margins derived.

Pre-FY22 reference points:

• FY21: revenue A$183.6m, underlying EBITDA A$47.7m, underlying NPAT A$23.4m (restated from A$23.3m adjusted NPAT for SaaS accounting), reported NPAT A$25.7m (FY24 Remuneration Report).

• FY20: revenue A$145.4m.

Underlying-to-statutory bridge

FY25 class-action line is a net credit of A$3.75m. This is consistent with insurance-related recoveries following the Federal Court action against CGU; the underlying cause was not confirmed in the extracted text.

FY26 incident costs exclude up to A$2.8m pre-tax of potential insurance recoveries, disclosed as a contingent asset and not recognised.

Balance sheet (FY23–FY26, summary basis as reported)

Notes:

Short/long-term debt split: Borrowings are presented as a single line in the summary balance sheet and are drawn under a syndicated facility. The facility was extended in Aug 2026, which implies a long-term classification.

Goodwill dominance: Goodwill and intangibles equal about 117% of equity, so net tangible assets per share are negative (−8.57c in FY26; −10.71c in FY25).

FY24 working capital: The FY24 net working capital includes A$64.4m class-action payable and A$19.9m insurance receivable.

Cash flow (FY23–FY26)

Company definition of free cash flow: operating cash flow less investing cash flow.

FY25 operating cash flow was depressed by a A$49.6m working-capital outflow, mainly NiPGT settlement instalments.

FY26 capex mix: Brisbane A$10.9m; laboratory and medical equipment A$7.9m; IT A$5.0m.

Buybacks: none disclosed in FY23–FY26.

FY26 also included: A$0.7m dividends to non-controlling interests and A$1.8m lease incentives received.

Ratios

Data conflicts and limitations:

FY24 ROE: The FY24 Directors' Report shows ROE of 12.1% in the summary table and 10.7% in the capital-metrics table. Both figures are reported; the difference likely reflects definitional changes.

Covenant limits: Net leverage covenant is ≤3.5x and interest cover covenant is ≥3.0x (FY24 Financial Report).

Cash conversion cycle: Not meaningful and not disclosed. The business collects most patient fees upfront and runs structurally negative working capital.

Half-year profile (FY26)

Sources: 1H26 results (InvestSMART summary of ASX release); 2H derived as FY26 minus 1H26.

Commentary on trends, inflections and drivers

FY22–FY24: acquisition-led growth. Revenue rose 33% from A$192.3m to A$255.0m. Drivers were:

• Bolt-on acquisitions: ART Associates, PIVET, Fertility North

• New day hospitals generating facility-fee revenue

• Price rises of 5–8% in FY24

• Doctor recruitment

Underlying EBITDA margin held around 25%. Underlying NPAT reached a post-IPO record of A$29.9m in FY24. That year was overshadowed statutorily by the A$32.6m after-tax NiPGT settlement charge.

FY25: the inflection. Revenue still grew 6.7% and underlying EBITDA 5.6%. However, underlying NPAT fell 8.1%, because higher depreciation from new facilities and higher interest diluted earnings. Domestic stimulated cycles fell 5.0% against an industry decline of 1.7%. More than 90% of the decline was in Victoria. Then the April and June 2025 incidents broke.

The balance sheet absorbed:

• Class-action cash payments, which crushed FY25 operating cash flow to A$12.9m

• Continued capex

Net debt nearly doubled to A$89.6m.

FY26: the trough year. Revenue was resilient (−0.9%), thanks to genetics, storage, ultrasound pricing and Asia. Earnings fell sharply:

• Underlying EBITDA −19.5% to A$53.4m

• Underlying NPAT −41.2% to A$16.1m

The causes were operating deleverage on a largely fixed clinical cost base, deferral of East Coast price rises (about A$6.1m EBITDA), wage inflation, A$4.5m of incident-related costs (below the line) and a A$1.4m after-tax prepaid-asset write-off (above the line).

Statutory NPAT fell 67.6% to A$8.3m. Cash generation improved materially: operating cash flow was A$36.7m and free cash flow A$12.9m, as class-action outflows ceased. Leverage still rose to 1.9x because of the Brisbane build.

The 2H26 earnings run-rate (about A$5.7m underlying NPAT) was weaker than 1H26 even as market share recovered. This is a key point for valuation: the recovery case depends on FY27 pricing, volume conversion and cost-out, not on momentum already visible in reported earnings.

Management guidance

• No numeric FY27 earnings guidance was given at the FY26 result. Management expects performance to strengthen through FY27, citing:

  • Improving market conditions

  • Market-share gains

  • Increased medical capacity

  • Pricing initiatives

  • Momentum in International, Genetics and Diagnostics

  • Productivity measures

• FY27 capex is guided down about 50%.

• Medium-to-long-term growth is guided to mid-to-high single-digit revenue and earnings CAGRs.

• A further update is promised at the AGM (scheduled for late October 2026).

Consensus growth expectations

The latest verified consensus data point is Visible Alpha's FY26 underlying NPAT expectation of about A$26.4m, recorded in Aug 2025. Actual was A$16.1m, illustrating the scale of earnings revision.

Bull case

1. Earnings trough with visible self-help. About A$6.1m of FY26 EBITDA was lost to deferred pricing alone. Restoring price, together with a ~50% capex cut, Brisbane ramp-up and the productivity program, could lift underlying NPAT materially from A$16.1m on minimal volume growth, given the fixed-cost base that magnified the downturn.

2. Share momentum and regulatory tailwind. Domestic share recovered from 19.0% (1H26) to 20.2% (2H26). Clinical outcomes exceed ANZARD, and national standards should favour scaled, well-governed operators.

3. Strategic floor from corporate interest. A 19.6% holder has twice bid (80c, then 90c), and the board deems 90c inadequate. With shares at roughly 72–82c, there is takeover optionality plus a 3%+ fully franked yield.

Bear case

1. Demand is cyclical after all. Industry stimulated cycles fell 4.7% in Feb–Apr 2026. The 2H26 underlying NPAT run-rate (about A$5.7m) was below 1H26 despite share gains, showing that a fixed-cost structure punishes volume weakness.

2. Execution and credibility risk. Three guidance cuts and a final miss in FY26, no permanent CFO, an almost entirely new executive team and board chair, and a still-fresh reputational wound in Victoria and Queensland.

3. Balance-sheet and returns drag. Net debt is A$101.2m (1.9x), lease liabilities A$90.2m, ROE 6% and derived ROIC about 6%. A goodwill-heavy balance sheet (A$295.6m) limits flexibility. A further incident, cyber event or litigation could quickly stress both earnings and the dividend.

Key catalysts and monitorables (next 12 months)

Analyst verdict

Monash IVF enters FY27 as a fundamentally sound franchise in a damaged state.

What is strong. The core assets are intact and arguably better than at any time since the 2014 IPO:

• A national clinic network with new flagship day hospitals in Melbourne, the Gold Coast and Brisbane

• An in-house genetics laboratory growing more than 20% in key tests

• An Asian business delivering record earnings

• Clinical success rates comfortably above the national benchmark

These are the attributes that new national accreditation should reward.

What the numbers show. The past 18 months exposed three uncomfortable truths. Patient-safety systems at the company were not as robust as its brand implied. IVF demand is more cyclical than the long-standing defensive thesis assumed. And the cost base is highly operationally geared, so a 1% revenue decline produced a 41% fall in underlying profit.

The reset. The board's response has been substantive rather than cosmetic:

• A clinician-governance CEO in Dr Atkinson

• A dedicated Chief Medical Officer recruited from the largest competitor

• Board renewal

• A refinancing that removes near-term maturity risk

What the valuation implies. At roughly 9–10x FY26 trough EV/EBITDA and below both rejected proposals, the market is discounting continued execution risk more than franchise impairment.

The recovery path. Earnings recovery depends on near-term levers that are largely within management's control: price restoration (about A$6m EBITDA), the capex step-down, Brisbane utilisation and cost-out. Volume recovery is less controllable but provides upside.

Downside guards. The 19.6% consortium stake provides a quasi-floor and genuine control optionality. However, it also concentrates negotiating power with a single bidder.

Verdict. On balance, the risk/reward is cautiously constructive for patient, event-tolerant investors, contingent on three tests over the next two reporting periods:

1. Domestic share sustained at or above 20%

2. Visible margin recovery in 1H27

3. No further clinical incidents

Failure on any one would likely re-anchor value toward the consortium's prior offers rather than toward the board's view of intrinsic worth.